THE IMPORTANCE OF THE HUMAN PAPILLOMAVIRUS (HPV) VACCINE IN THE PREVENTION OF CERVICAL CANCER
Keywords:
Cervical cancer, HPV, vaccine, prevention, immunization, cervical intraepithelial tumors.Abstract
Cervical cancer is a serious public health problem and one of the most common cancers among women worldwide. Early diagnosis and prevention play a crucial role in reducing the risk of its development. The primary etiologic factor for this disease is the human papillomavirus (HPV), and high-risk types lead to malignant transformation. This research presents an in-depth analysis of the preventive efficacy and clinical and epidemiological significance of the HPV vaccine. The analysis demonstrated that vaccination is highly effective in preventing cervical cancer, especially when administered at an early age, providing maximum protection. It was also shown that widespread implementation of vaccination programs in developed countries has significantly reduced the incidence of the disease. This article provides a scientifically based discussion of the benefits, practical challenges, and prospects of vaccination.
References
Arbyn M, Simoens C, Martin-Hirsch P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. // Cochrane Database of Systematic Reviews. 2018. Issue 5. Art. №.CD009069.
Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. // Vaccine. 2018. Vol. 36. P. 4761-4767.
Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. // Int. J. Cancer. 2018. Vol. 142, N 10. P. 2186-2187.
Patel C, Brotherton J, Pillsbury A et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? // Euro Surveill. 2018. Vol. 23, N 41.
Steben M, Thompson MT, Rodier C et al. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada. // Journal of Obstetrics and Gynaecology. 2018. Vol. 40. P. 1635-1645.
Ghelardi A, Ghelardi F, Martella F et al. SPERANZA project: HPV vaccination after treatment for CIN2+. // Gynecologic Oncology. 2018. Vol. 151, N 2. P. 229-234.
Guo F, Cofie LE, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. // Am J Prev Med. 2018. Vol. 55, N 2. P. 197-204.
Зароченцева Н.В., Трушина О.И., Новикова Е.Г., Баранов И.И., Лопухов П.Д., Ровинская О.В. Вакцинация против ВПЧ: теоретические аспекты и практические результаты профилактики рака шейки матки. Эпидемиология и Вакцинопрофилактика. 2019;18(6):98-108. https://doi.org/10.31631/2073-3046-2019-18-6-98-108 [Scopus]
Намазова-Баранова Л.С., Чемакина Д.С., Вишнева Е.А. и др. Обзор вакцинации против папилломавирусной инфекции в мире. // Педиатрическая фармакология. 2018. Т. 15, № 1. С. 80-85.
Kjaer SK, Nygard M, Dillner J et al. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. // Clin Infect Dis. 2017. Vol. 66. P. 339-345.
Вакцинопрофилактика заболеваний, вызванных вирусом папилломы человека: федер. клинич. рекомендации. // МЗ РФ, Союз педиатров России. М.: Педиатр; 2017. 40 с.
Прилепская В.Н. Вакцинация против ВПЧ-ассоциированных заболеваний и рака шейки матки. // Медицинский совет. 2016. № 12. С. 120-5.
Garland SM. Kjaer SK, Muñoz N et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. // CID. 2016. Vol. 63. P. 519-27.
Каприн А. Д., Новикова Е. Г., Трушина О. И., Грецова О. П. Скрининг рака шейки матки - нерешенные проблемы. // «Исследования и практика в медицине». 2015. Т. 2, № 1. С. 36-40.
Hariri S, Bennett NM, Niccolai LM et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. // Vaccine. 2015. Vol. 33. P. 1608-1613.
Downloads
Published
Issue
Section
How to Cite
